Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Tumor-infiltrating T cells, particularly CD45RO+ CD8+ memory T cells, confer a positive
prognostic value in human cancers. However, the mechanisms that promote a protective T …

Recently, the long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) has
been identified as an oncogenic gene in multiple human tumor entitles, and dysregulation of …

The development and clinical application of inhibitors that target the epidermal growth factor
receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …

Background Current clinical therapy of non-small cell lung cancer depends on histo-
pathological classification. This approach poorly predicts clinical outcome for individual …

Although most lung cancers are a result of smoking, approximately 25% of lung cancer
cases worldwide are not attributable to tobacco use, accounting for over 300,000 deaths …

Lung cancer is the leading cause of cancer-related death in the United States. An estimated
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …

Purpose It has been established that the immune system plays an important role in tumor
rejection. There is also compelling evidence that immune responses can develop …

Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …